Kura Oncology, Inc.
KURA
$5.95
$0.223.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 67.99M | 53.88M | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 67.99M | 53.88M | -- | -- | -- |
| Cost of Revenue | 211.32M | 191.62M | 36.27M | 36.27M | 36.27M |
| Gross Profit | -143.33M | -137.73M | -36.27M | -36.27M | -36.27M |
| SG&A Expenses | 81.76M | 77.11M | 67.27M | 62.24M | 57.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 271.43M | 247.08M | 217.50M | 200.09M | 183.69M |
| Operating Income | -203.44M | -193.20M | -217.50M | -200.09M | -183.69M |
| Income Before Tax | -179.64M | -171.97M | -197.55M | -181.75M | -168.09M |
| Income Tax Expenses | 2.24M | 2.02M | -- | -- | -- |
| Earnings from Continuing Operations | -181.89 | -173.98 | -197.55 | -181.75 | -168.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -181.89M | -173.98M | -197.55M | -181.75M | -168.09M |
| EBIT | -203.44M | -193.20M | -217.50M | -200.09M | -183.69M |
| EBITDA | -202.59M | -192.35M | -216.64M | -199.23M | -182.81M |
| EPS Basic | -2.09 | -2.02 | -2.36 | -2.23 | -2.18 |
| Normalized Basic EPS | -1.38 | -1.34 | -1.55 | -1.47 | -1.44 |
| EPS Diluted | -2.09 | -2.02 | -2.36 | -2.23 | -2.18 |
| Normalized Diluted EPS | -1.38 | -1.34 | -1.55 | -1.47 | -1.44 |
| Average Basic Shares Outstanding | 348.14M | 344.63M | 334.83M | 325.12M | 308.28M |
| Average Diluted Shares Outstanding | 348.14M | 344.63M | 334.83M | 325.12M | 308.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |